Baseline treatment group characteristics at initiation of treatment line
| . | 2L . | 2L-4L . | ||||
|---|---|---|---|---|---|---|
| . | Kd (n = 346) . | Vd (n = 825) . | P . | Kd (n = 543) . | Vd (n = 1005) . | P . |
| Age, n (%) | .0442 | .0062 | ||||
| <65 y | 88 (25.4) | 166 (20.1) | 148 (27.3) | 212 (21.1) | ||
| ≥65 y | 258 (74.6) | 659 (79.9) | 395 (72.7) | 793 (78.9) | ||
| Sex, n (%) | .4983 | .5319 | ||||
| Female | 172 (49.7) | 428 (51.9) | 273 (50.3) | 522 (51.9) | ||
| Male | 174 (50.3) | 397 (48.1) | 270 (49.7) | 483 (48.1) | ||
| Race, n (%) | .1872 | .0678 | ||||
| White | 232 (67.1) | 582 (70.5) | 367 (67.6) | 703 (70.0) | ||
| African American | 51 (14.7) | 90 (10.9) | 80 (14.7) | 112 (11.1) | ||
| Asian | 8 (2.3) | 9 (1.1) | 10 (1.8) | 9 (0.9) | ||
| Hispanic | 2 (0.6) | 3 (0.4) | 5 (0.9) | 3 (0.3) | ||
| Other | 31 (9.0) | 66 (8.0) | 46 (8.5) | 83 (8.3) | ||
| Missing | 22 (6.4) | 75 (9.1) | 35 (6.4) | 95 (9.5) | ||
| ECOG PS, n (%) | <.0001 | <.0001 | ||||
| 0-1 | 179 (51.7) | 318 (38.5) | 254 (46.8) | 382 (38.0) | ||
| ≥2 | 60 (17.3) | 100 (12.1) | 101 (18.6) | 114 (11.3) | ||
| Missing | 107 (30.9) | 407 (49.3) | 188 (34.6) | 509 (50.6) | ||
| eGFR values, n (%) | .0683 | .2243 | ||||
| 45-59 mL/min/ per 1.73 m2 | 98 (28.3) | 213 (25.8) | 154 (28.4) | 262 (26.1) | ||
| 30-44 mL/min per 1.73 m2 | 136 (39.3) | 376 (45.6) | 224 (41.3) | 465 (46.3) | ||
| 15-29 mL/min per 1.73 m2 | 75 (21.7) | 179 (21.7) | 116 (21.4) | 206 (20.5) | ||
| <15 mL/min per 1.73 m2 | 37 (10.7) | 57 (6.9) | 49 (9.0) | 72 (7.2) | ||
| ISS stage, n (%) | .3220 | .0542 | ||||
| I | 37 (10.7) | 120 (14.5) | 53 (9.8) | 144 (14.3) | ||
| II | 65 (18.8) | 155 (18.8) | 93 (17.1) | 178 (17.7) | ||
| III | 78 (22.5) | 166 (20.1) | 125 (23.0) | 202 (20.1) | ||
| Most common 1L treatment regimen, n (%) | ||||||
| Most common | BTZ+DEX, 150 (43.4) | BTZ+DEX, 315 (38.2) | BTZ+DEX, 236 (43.5) | BTZ+DEX, 378 (37.6) | ||
| Second most common | BTZ+LEN+DEX, 81 (23.4) | LEN+DEX, 202 (24.5) | BTZ+LEN+DEX, 109 (20.1) | LEN+DEX, 223 (22.2) | ||
| Third most common | BTZ+CP+DEX, 47 (13.6) | BTZ+CP+DEX, 87 (10.5) | BTZ+CP+DEX, 76 (14.0) | BTZ+CP+DEX, 114 (11.3) | ||
| Other regimen | 68 (19.7) | 221 (26.8) | 122 (22.5) | 290 (28.9) | ||
| Year of line initiation | <.0001 | <.0001 | ||||
| Prior to 2012 | 0 | 126 (15.3) | 0 | 152 (15.1) | ||
| 2012 | 25 (7.2) | 88 (10.7) | 38 (7.0) | 117 (11.6) | ||
| 2013 | 55 (15.9) | 118 (14.3) | 80 (14.7) | 136 (13.5) | ||
| 2014 | 52 (15.0) | 128 (15.5) | 89 (16.4) | 150 (14.9) | ||
| 2015 | 69 (19.9) | 134 (16.2) | 111 (20.4) | 161 (16.0) | ||
| 2016 | 85 (24.6) | 119 (14.4) | 132 (24.3) | 150 (14.9) | ||
| 2017 | 56 (16.2) | 99 (12.0) | 86 (15.8) | 123 (12.2) | ||
| 2018 | 4 (1.2) | 13 (1.6) | 7 (1.3) | 16 (1.6) | ||
| Serum calcium, mean mg/dL, (SD) | 9.1 (0.8) | 9.2 (0.7) | .0309 | 9.1 (0.8) | 9.2 (0.8) | .0021 |
| Serum free light-chain ratio, mean (SD) | 245.5 (883.0) | 43.2 (144.8) | .0051 | 214.0 (766.4) | 75.0 (464.4) | .0078 |
| Serum LDH, mean U/L, (SD) | 255.8 (158.8) | 205.7 (110.5) | .0004 | 257.1 (160.5) | 204.9 (107.2) | <.0001 |
| Whole blood hemoglobin, mean g/dL, (SD) | 10.4 (1.6) | 11.0 (1.7) | <.0001 | 10.4 (1.6) | 10.9 (1.6) | <.0001 |
| . | 2L . | 2L-4L . | ||||
|---|---|---|---|---|---|---|
| . | Kd (n = 346) . | Vd (n = 825) . | P . | Kd (n = 543) . | Vd (n = 1005) . | P . |
| Age, n (%) | .0442 | .0062 | ||||
| <65 y | 88 (25.4) | 166 (20.1) | 148 (27.3) | 212 (21.1) | ||
| ≥65 y | 258 (74.6) | 659 (79.9) | 395 (72.7) | 793 (78.9) | ||
| Sex, n (%) | .4983 | .5319 | ||||
| Female | 172 (49.7) | 428 (51.9) | 273 (50.3) | 522 (51.9) | ||
| Male | 174 (50.3) | 397 (48.1) | 270 (49.7) | 483 (48.1) | ||
| Race, n (%) | .1872 | .0678 | ||||
| White | 232 (67.1) | 582 (70.5) | 367 (67.6) | 703 (70.0) | ||
| African American | 51 (14.7) | 90 (10.9) | 80 (14.7) | 112 (11.1) | ||
| Asian | 8 (2.3) | 9 (1.1) | 10 (1.8) | 9 (0.9) | ||
| Hispanic | 2 (0.6) | 3 (0.4) | 5 (0.9) | 3 (0.3) | ||
| Other | 31 (9.0) | 66 (8.0) | 46 (8.5) | 83 (8.3) | ||
| Missing | 22 (6.4) | 75 (9.1) | 35 (6.4) | 95 (9.5) | ||
| ECOG PS, n (%) | <.0001 | <.0001 | ||||
| 0-1 | 179 (51.7) | 318 (38.5) | 254 (46.8) | 382 (38.0) | ||
| ≥2 | 60 (17.3) | 100 (12.1) | 101 (18.6) | 114 (11.3) | ||
| Missing | 107 (30.9) | 407 (49.3) | 188 (34.6) | 509 (50.6) | ||
| eGFR values, n (%) | .0683 | .2243 | ||||
| 45-59 mL/min/ per 1.73 m2 | 98 (28.3) | 213 (25.8) | 154 (28.4) | 262 (26.1) | ||
| 30-44 mL/min per 1.73 m2 | 136 (39.3) | 376 (45.6) | 224 (41.3) | 465 (46.3) | ||
| 15-29 mL/min per 1.73 m2 | 75 (21.7) | 179 (21.7) | 116 (21.4) | 206 (20.5) | ||
| <15 mL/min per 1.73 m2 | 37 (10.7) | 57 (6.9) | 49 (9.0) | 72 (7.2) | ||
| ISS stage, n (%) | .3220 | .0542 | ||||
| I | 37 (10.7) | 120 (14.5) | 53 (9.8) | 144 (14.3) | ||
| II | 65 (18.8) | 155 (18.8) | 93 (17.1) | 178 (17.7) | ||
| III | 78 (22.5) | 166 (20.1) | 125 (23.0) | 202 (20.1) | ||
| Most common 1L treatment regimen, n (%) | ||||||
| Most common | BTZ+DEX, 150 (43.4) | BTZ+DEX, 315 (38.2) | BTZ+DEX, 236 (43.5) | BTZ+DEX, 378 (37.6) | ||
| Second most common | BTZ+LEN+DEX, 81 (23.4) | LEN+DEX, 202 (24.5) | BTZ+LEN+DEX, 109 (20.1) | LEN+DEX, 223 (22.2) | ||
| Third most common | BTZ+CP+DEX, 47 (13.6) | BTZ+CP+DEX, 87 (10.5) | BTZ+CP+DEX, 76 (14.0) | BTZ+CP+DEX, 114 (11.3) | ||
| Other regimen | 68 (19.7) | 221 (26.8) | 122 (22.5) | 290 (28.9) | ||
| Year of line initiation | <.0001 | <.0001 | ||||
| Prior to 2012 | 0 | 126 (15.3) | 0 | 152 (15.1) | ||
| 2012 | 25 (7.2) | 88 (10.7) | 38 (7.0) | 117 (11.6) | ||
| 2013 | 55 (15.9) | 118 (14.3) | 80 (14.7) | 136 (13.5) | ||
| 2014 | 52 (15.0) | 128 (15.5) | 89 (16.4) | 150 (14.9) | ||
| 2015 | 69 (19.9) | 134 (16.2) | 111 (20.4) | 161 (16.0) | ||
| 2016 | 85 (24.6) | 119 (14.4) | 132 (24.3) | 150 (14.9) | ||
| 2017 | 56 (16.2) | 99 (12.0) | 86 (15.8) | 123 (12.2) | ||
| 2018 | 4 (1.2) | 13 (1.6) | 7 (1.3) | 16 (1.6) | ||
| Serum calcium, mean mg/dL, (SD) | 9.1 (0.8) | 9.2 (0.7) | .0309 | 9.1 (0.8) | 9.2 (0.8) | .0021 |
| Serum free light-chain ratio, mean (SD) | 245.5 (883.0) | 43.2 (144.8) | .0051 | 214.0 (766.4) | 75.0 (464.4) | .0078 |
| Serum LDH, mean U/L, (SD) | 255.8 (158.8) | 205.7 (110.5) | .0004 | 257.1 (160.5) | 204.9 (107.2) | <.0001 |
| Whole blood hemoglobin, mean g/dL, (SD) | 10.4 (1.6) | 11.0 (1.7) | <.0001 | 10.4 (1.6) | 10.9 (1.6) | <.0001 |
BTZ, bortezomib; CP, cyclophosphamide; DEX, dexamethasone; EOT, end of treatment; LEN, lenalidomide; SD, standard deviation.